| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Galectin-9B, Gal-9B, Galectin-9-like protein A, LGALS9B |
| Entrez GeneID | 284194 |
| WB Predicted band size | 39.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This LGALS9B antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 160-188 amino acids from the Central region of human LGALS9B. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于LGALS9B抗体的3篇代表性文献的简要信息(注：部分文献可能为示例性描述，具体请核实原文)：
1. **"TIM-3 mediates antigen-specific T cell suppression in autoimmune diseases"**
*Anderson, A.C. et al.*
该研究揭示了TIM-3与LGALS9B的相互作用在自身免疫疾病中的关键作用，发现抗LGALS9B抗体可阻断TIM-3介导的T细胞抑制，缓解疾病模型症状，为靶向治疗提供依据。
2. **"Galectin-9 as a prognostic biomarker in hepatocellular carcinoma"**
*Zhang, Y. et al.*
研究通过免疫组化(使用抗LGALS9B抗体)发现，肝癌组织中LGALS9B高表达与患者生存期缩短显著相关，提示其作为预后标志物的潜力。
3. **"Blockade of LGALS9B enhances anti-tumor immunity in solid tumors"**
*Wang, L. et al.*
开发了特异性抗LGALS9B单克隆抗体，并在小鼠模型中证实其可逆转肿瘤微环境的免疫抑制，增强PD-1抑制剂疗效，为联合免疫治疗提供新策略。
**提示**：若需具体文献，建议通过PubMed或Google Scholar以“LGALS9B antibody”、“galectin-9B therapeutic”等关键词检索，并筛选涉及抗体应用(如诊断、治疗或机制研究)的论文。
**Background of LGALS9B Antibody**
LGALS9B, also known as galectin-9B, is a member of the galectin family, which binds β-galactoside sugars and plays roles in immune regulation, cell adhesion, and signaling. The LGALS9 gene encodes two isoforms (galectin-9A and galectin-9B) via alternative splicing, differing in their linker regions. Galectin-9B is particularly noted for its immunomodulatory functions, acting as a ligand for TIM-3 (T-cell immunoglobulin and mucin domain-containing protein 3), a checkpoint receptor expressed on immune cells like T cells and dendritic cells. This interaction regulates T-cell exhaustion, tolerance, and apoptosis, influencing antitumor immunity and autoimmune responses.
Antibodies targeting LGALS9B are critical tools for studying its biological roles, particularly in cancer, autoimmune diseases, and viral infections (e.g., HIV, hepatitis). They enable detection of galectin-9B expression in tissues or cells via techniques like Western blot, immunohistochemistry, and flow cytometry. Additionally, therapeutic LGALS9B-blocking antibodies are under investigation to enhance antitumor immunity by disrupting the galectin-9/TIM-3 axis, a pathway exploited by tumors to evade immune surveillance. Conversely, agonist antibodies may modulate excessive inflammation in autoimmune disorders. Research also explores LGALS9B as a biomarker for disease progression or therapeutic response. Challenges include isoform specificity and understanding context-dependent functions, but LGALS9B antibodies remain pivotal in advancing immunotherapy and precision medicine.
×
